What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?

Click to increase image sizeClick to decrease image size

Declaration of interest

In addition to his academic positions, JA Hartley was a founder scientist of Spirogen Ltd and has an equity interest in ADC Therapeutics. He is also on the Scientific Advisory Board of Spirea Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.